Positions

Principal Investigator On

  • GBM Avatar Screening Paradigm for Rational Pharmacokinomic Glioma Therapy  awarded by National Cancer Institute/NIH/DHHS 2020 - 2022
  • Private Grant  awarded by IN8BIO INC. 2019 - 2020
  • Private Grant  awarded by VIVO BIOSCIENCES, INC. 2015 - 2017
  • Contemporary Therapeutics for Anaplastic Gliomas  awarded by National Cancer Institute/NIH/DHHS 2011 - 2017
  • COMPLETED - Comprehensive Cancer Center Core Support Grant - Neuro-Oncology Program  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Contemporary Therapeutics for Anaplastic Gliomas - Administrative Core  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Contemporary Therapeutics for Anaplastic Gliomas - Animal Models  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Contemporary Therapeutics for Anaplastic Gliomas - Brain Tumor Tissue Core  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Engineered HSV for the Treatment of Malignant Gliomas - Core B (Animal Model) - Experimental Glioma Animal Models  awarded by National Cancer Institute/NIH/DHHS 2009 - 2015
  • Interrogation of Key Genomic Alterations in Glioblastoma Multiforme (GBM) for Identification of Molecular Pathways Critical to GBM Tumorigenesis and Progression  awarded by SOUTHERN RESEARCH INSTITUTE 2013 - 2015
  • American Cancer Society Post Doctoral Fellowship, Tumor Specific Targeted Oncolytic Virotherapy Using Genetically Engineered Adenovirus  awarded by American Cancer Society, Inc. 2012 - 2014
  • Private Grant  awarded by VIVO BIOSCIENCES, INC. 2013 - 2014
  • Interrogation of Key Genomic Alterations in Glioblastoma Multiforme (GBM) for Identification of Molecular Pathways Critical to GBM Tumorigenesis and Progression  awarded by SOUTHERN RESEARCH INSTITUTE 2010 - 2012
  • Molecular Therapeutics for Anaplastic Gliomas - Core A  awarded by National Cancer Institute/NIH/DHHS 2005 - 2011
  • Molecular Therapeutics for Anaplastic Gliomas  awarded by National Cancer Institute/NIH/DHHS 2004 - 2011
  • Molecular Therapeutics for Anaplstic Gliomas - Core D  awarded by National Cancer Institute/NIH/DHHS 2004 - 2011
  • Human GBM Xenograft Chemovulnerability and Genomic Profiling  awarded by Translational Genomics Research Institute (TGen) 2008 - 2011
  • Molecular Therapeutics for Anaplastic Gliomas - Career Development  awarded by National Cancer Institute/NIH/DHHS 2005 - 2008
  • Molecular Therapeutics for Anaplastic Gliomas - Pilot Projects  awarded by National Cancer Institute/NIH/DHHS 2005 - 2007
  • Molecular Therapeutics for Anaplastic Gliomas - Project 4 Consortium  awarded by National Cancer Institute/NIH/DHHS 2004 - 2007
  • Investigator On

  • Oncolytic Immunotherapy Using Chimeric HSV C134: A Phase I Trial and Establishment of Response Indicators in Recurrent Glioma Patients  awarded by BECKMAN RESEARCH INSTITUTE (CITY OF HOPE) 2020 - 2025
  • Tissue-Regulated Lineage-Specific Splicing in Glioblastoma Pathogenesis  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2020 - 2024
  • Biological Comparisons Among Three Derivative Models of Glioma Patient Cancers Under Microenvironmental Stress  awarded by National Cancer Institute/NIH/DHHS 2018 - 2023
  • NN106 Cytochrome C Oxidase Activity In Newly Diagnosed Glioblastoma Multiforme (GBM)  awarded by MASSACHUSETTS GENERAL HOSPITAL 2016 - 2023
  • Biosynthetic Metabolic Pathway Regulation of Glioma Growth  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2017 - 2022
  • A Phase I Trial of IRS-1 HSV C134 Administered Intratumorally in Patients with Recurrent Malignant Glioma  awarded by Gateway for Cancer Research (The) 2019 - 2022
  • Canine Immuno Neurotherapeutics  awarded by National Cancer Institute/NIH/DHHS 2017 - 2022
  • Oncolytic Immunotherapy Using Chimeric HSV C134: A Phase I Trial and Establishment of Response Indicators in Recurrent Glioma Patients  awarded by National Cancer Institute/NIH/DHHS 2018 - 2021
  • Boosting the Systemic and in Situ CD4+ T-Cell Responses to Malignant Glioma by Oncolytic HSV Virotherapy  awarded by DOD - Department of Defense 2018 - 2021
  • Dual PET/Fluorescence Imaging of Glioma with an MMP-14 Activabable Peptide Probe  awarded by DOD - Department of Defense 2018 - 2021
  • Targeting PRMT5 in Cancer Initiating Cells as a New Therapy for Glioblastoma  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2015 - 2021
  • A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma  awarded by National Cancer Institute/NIH/DHHS 2017 - 2020
  • Ph1 of HSV G207 and Radiation to Treat Pediatric Brain Tumors IND 16294 (12/10/14)  awarded by Food & Drug Administration 2016 - 2020
  • Private Grant  awarded by CHAMPIONS ONCOLOGY 2018 - 2020
  • lmmunovirotherapy to Target Pediatric Brain Tumors  awarded by KAUL PEDIATRIC RESEARCH INSTITUTE 2018 - 2020
  • Expansion of G207 Trial  awarded by CANNONBALL KIDS' CANCER FOUNDATION 2017 - 2020
  • Intraventricular Delivery of Engineered Oncolytic Herpes Simplex Virotherapy to Treat Localized and Metastatic Pediatric Brain Tumors  awarded by DOD - ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY 2015 - 2019
  • MARCKS as a Novel Regulator of Glioblastoma Growth and Treatment Resistance  awarded by American Cancer Society, Inc. 2014 - 2019
  • Enhancement of lmmunovirotherapy with IDO Inhibition in Pediatric Medulloblastoma  awarded by HYUNDAI HOPE ON WHEELS 2016 - 2018
  • Cytochrome C Oxidase: Biomarker In Newly Diagnosed Glioblastoma Multiforme  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2016 - 2018
  • Paracrine Signaling in Glioma: Bioenergetics Heterogeneity and Chemoresistance  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2016 - 2018
  • Cytochrome C Oxidase in Malignant Gliomas  awarded by National Cancer Institute/NIH/DHHS 2012 - 2018
  • UAB Research and Education Program in Neurology, Neurosurgery, and Neuropathology  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2012 - 2017
  • Targeting Pediatric Medulloblastoma with Engineered Herpes Simplex Virus  awarded by RALLY FOUNDATION 2016 - 2017
  • Engineered Oncolytic Herpes Simplex Virotherapy for Medulloblastomas  awarded by St. Baldrick's Foundation 2012 - 2017
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Lumina III System for UAB Optical Imaging  awarded by NIH - OFFICE OF THE DIRECTOR 2016 - 2017
  • 3D-Microtumor_GBM Xenoline Proband Modeling of Kinome-Directed Therapy  awarded by National Cancer Institute/NIH/DHHS 2014 - 2017
  • Role of CL-Channels and Transporters in Tumor-Associated Epilepsy  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2014 - 2016
  • Active - Major Program Leader - Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2011 - 2016
  • Evaluation pf Clinically-ready Oncolytic HSV in Pediatric Brain Tumors  awarded by HYUNDAI HOPE ON WHEELS 2013 - 2015
  • Engineered Herpes Simplex Virus for Treatment of Malignant Peripheral Nerve Sheath Tumors  awarded by DOD - ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY 2011 - 2015
  • Amino Acid Transport and the Biology of Human Gliomas  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS 2011 - 2015
  • Engineered HSV for the Treatment of Malignant Glioma  awarded by National Cancer Institute/NIH/DHHS 2009 - 2015
  • Engineered HSV for the Treatment of Malignant Glioma - Core A. Administrative Core  awarded by National Cancer Institute/NIH/DHHS 2009 - 2015
  • Engineered HSV for the Treatment of Malignant Glioma - Project 3 - Preclinical Evaluation of Oncolytic HSV for Anaplastic Glioma Therapy  awarded by National Cancer Institute/NIH/DHHS 2009 - 2015
  • Engineered HSV for the Treatment of Malignant Glioma - Project 4 - Lessons from the O.R.: Using Clinical Biologic Correlates to Inform HSV Trial Design  awarded by National Cancer Institute/NIH/DHHS 2009 - 2015
  • Targeting Pediatric Medulloblastoma with Engineered Herpes Simplex Virus  awarded by RALLY FOUNDATION 2014 - 2015
  • Negative Impact of RNA Destabilizer Tristetraprolin on Glioma Growth  awarded by National Cancer Institute/NIH/DHHS 2009 - 2014
  • Targeting Pediatric Medulloblastoma with Engineered Herpes Simplex Virus  awarded by RALLY FOUNDATION 2013 - 2014
  • Integrated Pharmacogenomic/Pharmacokinomic Approach to Optimize GBM Therapy  awarded by National Brain Tumor Society 2011 - 2013
  • Teaching Activities

    Education And Training

  • Doctor of Philosophy in Immunology, University of Mississippi 1971
  • Master of Science in Cytogenetics / Genetics / Clinical Genetics Technology / Technologist, University of Mississippi 1968
  • Bachelor of Arts in Biology, University of Mississippi 1965
  • Bachelor of Arts in Chemistry, University of Mississippi 1965
  • Full Name

  • George Gillespie